Fig. 8

PTGES3-PROTAC suppressed tumor growth in vivo. (A) Representative photographs of excised tumors from xenograft tumor models (n = 5). (B) The protein levels of PTGES3 expression in subcutaneous xenografts from the control, FIP-2 treatment and PTGES3-PROTAC treatment groups (n = 3). (C) Immunohistochemistry images of Ki67 and PTGES3 protein in xenograft tumors from the indicated groups (n = 3). (D) Subcutaneous xenograft masses were excised and weighed at the endpoint (n = 5). (E) Tumor growth curves of subcutaneous tumor formation in nude mice treated with FIP-2 or PTGES3-PROTAC (n = 5). (F) H&E staining of major organ tissues harvested from tumor-bearing nude mice subcutaneously injected with Hep3B cells. The results showed no systemic toxicity (n = 5). (G) Activities of serum alanine aminotransferase (ALT), aspartic acid transferase (AST), creatinine and blood urea nitrogen from nude mice subcutaneously injected with Hep3B cells (n = 5)